Core Viewpoint - Sanofi's innovative drug Cablivi has received approval from China's National Medical Products Administration (NMPA) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults and adolescents aged 12 and above weighing at least 40 kg [1] Group 1 - Cablivi is the first and only targeted nanobody drug approved for the treatment of iTTP globally [1] - The drug aims to provide faster disease control, reduce related mortality, worsening, or major thrombotic events, and prevent recurrence [1] - Cablivi offers a more effective and safer treatment option for patients [1]